कृपया अन्य खोज का प्रयास करें
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Sean A. McCarthy | 55 | 2011 | Chairman & CEO |
W. Michael Kavanaugh | 66 | 2015 | Member of Scientific Advisory Board |
Matthew P. Young | 53 | 2015 | Lead Independent Director |
James R. Meyers | 57 | 2018 | Independent Director |
Louis M. Weiner | 70 | - | Member of Scientific Advisory Board |
Elaine V. Jones | 67 | 2019 | Independent Director |
Halley E. Gilbert | 52 | 2020 | Independent Director |
Charles L. Sentman | - | 2020 | Member of Scientific Advisory Board |
John M. Lambert | 72 | 2020 | Member of Scientific Advisory Board |
Mani Mohindru | 51 | 2020 | Independent Director |
Lisa M. Coussens | - | 2023 | Member of Scientific Advisory Board |
Alan Ashworth | 62 | 2021 | Independent Director |
Christopher M. Overall | - | 2021 | Member of Scientific Advisory Board |
Zhen Su | - | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है